Results for tag: "Congenital Afibrinogenemia Drug"

Congenital afibrinogenemia is a rare inherited disorder that affects the body's ability to form blood clots. It is caused by a deficiency of the protein fibrinogen, which is essential for clotting. People with this disorder are at risk of excessive bleeding, even from minor injuries. Treatment for congenital afibrinogenemia typically involves the administration of fibrinogen concentrate, a type of hematological drug. Fibrinogen concentrate is a purified form of fibrinogen that is derived from human plasma. It is used to replace the missing fibrinogen in the blood of patients with congenital afibrinogenemia. The drug is administered intravenously, and the dose is adjusted according to the patient's individual needs. The congenital afibrinogenemia drug market is a small but growing segment of the hematological drugs market. It is driven by the increasing prevalence of the disorder, as well as the development of new treatments and technologies. Companies in this market include CSL Behring, Grifols, Octapharma, and Kedrion Biopharma. Show Less Read more